High Concentration Antibody Formulations Enabled via Thermostable Ionic Liquids
Source abstract
Abstract
ABSTRACT Concentrated protein formulations have garnered significant attention in both commercial and research domains due to their relevance in patient‐favored, subcutaneous administration. However, these formulations face challenges such as high viscosity and elevated potential for aggregation, primarily driven by intermolecular electrostatic and hydrophobic protein‐protein interactions (PPIs). Achieving an acceptable injectability profile (<20 cP) often necessitates the incorporation of excipients that mitigate PPIs through shielding effects. Current clinical formulations exhibit a narrow colloidal stability window, largely due to molecular changes under physical and thermal stress, whilst also suffering from suboptimal bioavailability (50%–85%). To address these limitations, we harness the utility of ionic liquids (ILs) that offer tunable charge and amphiphilicity profiles as a means to simplify and stabilize protein formulations. Herein, we synthesized biocompatible choline and organic acid‐based ILs and assessed their viscosity profiles with IgG antibody at both high (90 mg/mL) and ultra‐high (230 mg/mL) concentrations. Functional and structural stability assays conducted over 4 months at room temperature identified promising IL candidates for in vivo studies at both IgG concentrations. Through a multi‐tiered screening strategy, we generated thermally stable, ultra‐high concentration antibody solutions that achieved a five fold improvement in serum absorption of polyclonal IgG compared to their saline solutions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ionic liquids properties and applications · Advanced Drug Delivery Systems · Advanced Biosensing Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Harvard John A. Paulson School of Engineering and Applied Sciences Harvard University Allston Massachusetts USA
Wyss Institute for Biologically Inspired Engineering Boston Massachusetts USA
Funding
Harvard School of Engineering and Applied Sciences · Harvard Medical School
References (47)
Show source-provided references
1. AbbVie · 2002
2. AbbVie Inc · 2019
3. Genentech · 2017
4. Genentech · 2019
5. 10.1093/abt/tbab02710.1093/abt/tbab027 ↗
6. 10.1080/19420862.2023.220554010.1080/19420862.2023.2205540 ↗
7. 10.1016/j.jconrel.2018.08.00110.1016/j.jconrel.2018.08.001 ↗
8. 10.3111/13696998.2014.91403310.3111/13696998.2014.914033 ↗
9. 10.1007/s11523-014-0313-110.1007/s11523-014-0313-1 ↗
10. 10.2147/PPA.S8727110.2147/PPA.S87271 ↗
11. 10.1016/j.xphs.2018.01.00710.1016/j.xphs.2018.01.007 ↗
12. 10.1177/193229681773512110.1177/1932296817735121 ↗
13. 10.1111/cts.1310910.1111/cts.13109 ↗
14. Evaluation of the Impact of Viscosity, Injection Volume, and Injection Flow Rate on Subcutaneous Injection Tolerance
15. GlaxoSmithKline · 2011
16. 10.1007/s11095-021-03125-610.1007/s11095-021-03125-6 ↗
17. 10.1002/psp4.1222410.1002/psp4.12224 ↗
18. 10.1002/advs.20200481910.1002/advs.202004819 ↗
19. 10.1002/advs.20220538910.1002/advs.202205389 ↗
20. 10.1016/j.jconrel.2018.07.02910.1016/j.jconrel.2018.07.029 ↗
21. 10.1002/adma.20190110310.1002/adma.201901103 ↗
22. 10.1073/pnas.140399511110.1073/pnas.1403995111 ↗
23. 10.1002/adfm.20200291210.1002/adfm.202002912 ↗
24. 10.1016/j.jconrel.2020.07.03710.1016/j.jconrel.2020.07.037 ↗
25. 10.1002/adhm.20240032710.1002/adhm.202400327 ↗
26. 10.1039/C9CS00016J10.1039/C9CS00016J ↗
27. 10.1016/j.xphs.2021.11.00810.1016/j.xphs.2021.11.008 ↗
28. 10.1016/j.xphs.2017.06.01710.1016/j.xphs.2017.06.017 ↗
29. 10.1016/j.xphs.2020.12.01610.1016/j.xphs.2020.12.016 ↗
30. 10.1016/j.coche.2017.04.00110.1016/j.coche.2017.04.001 ↗
31. 10.1016/j.bpj.2013.01.00710.1016/j.bpj.2013.01.007 ↗
32. 10.1039/C3SM51994E10.1039/C3SM51994E ↗
33. 10.1529/biophysj.104.04774610.1529/biophysj.104.047746 ↗
34. 10.1016/S0006-3495(00)76602-110.1016/S0006-3495(00)76602-1 ↗
35. 10.1016/B978-0-12-420119-4.00007-010.1016/B978-0-12-420119-4.00007-0 ↗
36. 10.1063/1.47204610.1063/1.472046 ↗
37. 10.1016/j.xphs.2022.05.01110.1016/j.xphs.2022.05.011 ↗
38. 10.1002/adma.20240660410.1002/adma.202406604 ↗
39. 10.1016/j.csbj.2022.09.03510.1016/j.csbj.2022.09.035 ↗
40. 10.1016/j.xphs.2021.06.03010.1016/j.xphs.2021.06.030 ↗
41. 10.1002/adtp.20220010210.1002/adtp.202200102 ↗
42. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
43. 10.1007/978-3-319-20726-1_1410.1007/978-3-319-20726-1_14 ↗
44. 10.4161/mabs.4.1.1854310.4161/mabs.4.1.18543 ↗
45. 10.1080/19420862.2020.177002810.1080/19420862.2020.1770028 ↗
46. 10.1093/nar/gkac34510.1093/nar/gkac345 ↗
47. C57BL/6 Mouse Information (Charles River Laboratories 2012).